| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,192,753 ) |
| | 2024 | 2024 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44HL167473 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | 003 | 3 | NIH | 6/14/2024 | $1,192,753 |
| | 2024 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | UG3NS134781 | A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease | 000 | 1 | NIH | 1/9/2024 | $0 |
| | 2024 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44HL167473 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | 002 | 2 | NIH | 5/23/2024 | $0 |
| | 2024 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44HL167473 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | 000 | 1 | NIH | 2/12/2024 | -$114,061 |
| | 2024 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44HL167473 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | 001 | 2 | NIH | 2/12/2024 | $114,061 |
| | 2024 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | UG3NS134781 | A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease | 001 | 1 | NIH | 1/10/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $4,008,183 ) |
| | 2023 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44HL167473 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | 003 | 2 | NIH | 8/18/2023 | $1,117,633 |
| | 2023 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | UG3NS134781 | A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease | 000 | 1 | NIH | 9/18/2023 | $2,589,070 |
| | 2023 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44HL167473 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | 002 | 1 | NIH | 6/21/2023 | $0 |
| | 2023 | 2023 | IHP THERAPEUTICS, INC. | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44HL167473 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | 000 | 1 | NIH | 3/5/2023 | $301,480 |
| | 2023 | 2023 | IHP THERAPEUTICS, INC. | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R44HL167473 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease | 001 | 1 | NIH | 3/10/2023 | $0 |
| | 2023 | 2023 | IHP THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | UG3NS134781 | A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease | 001 | 1 | NIH | 9/21/2023 | $0 |
|
|
